DOI QR코드

DOI QR Code

Normalization of CA19-9 Following Resection for Pancreatic Ductal Adenocarcinoma is not Tantamount to being Cured?

  • Chen, Tao ;
  • Zhang, Min-Gui ;
  • Yu, Xian-Jun ;
  • Liu, Liang
  • Published : 2015.02.25

Abstract

Background: Postoperative carbohydrate antigen 19-9 (CA19-9) is an independent predictor of survival for pancreatic ductal adenocarcinoma (PDAC), and more powerful than preoperative CA19-9. However, making decisions just dependent on postoperative CA19-9 may result in necessary treatments not being performed. Materials and Methods: A total of 178 patients with resected PDAC were eligible for this retrospective study, classified into two corresponding subgroups according to postoperative CA19-9. Prognostic significance of all clinicopathologic factors was evaluated by univariate and multivariate analyses. Results: Postoperative CA19-9, preoperative CA125 and lymph node status were independent predictors. Better predictive performances for overall survival (OS) and recurrence-free survival (RFS) were achieved by postoperative CA19-9 compared to preoperative CA125 and lymph node status. Particularly, preoperative CA125 was associated with poor OS (p<0.001 for the normalized CA19-9 patients, p=0.012 for the elevated) and RFS (p=0.005 for the normalized, p=0.004 for the elevated). Moreover, preoperative CA125 levels related with survival in double-negative patients. Conclusions: Normalization of CA19-9 is not tantamount to be cured. Preoperative CA125 is a critical predictor for PDAC patients, especially in double-negative patients.

Keywords

Postoperative CA19-9;normalization;preoperative CA125;pancreatic ductal cancer;prognosis

References

  1. Abdel-Misih SR, Hatzaras I, Schmidt C, et al (2011). Failure of normalization of CA19-9 following resection for pancreatic cancer is tantamount to metastatic disease. Ann Surg Oncol, 18, 1116-21. https://doi.org/10.1245/s10434-010-1397-1
  2. Barugola G, Partelli S, Marcucci S, et al (2009). Resectable pancreatic cancer: who really benefits from resection? Ann Surg Oncol, 16, 3316-22. https://doi.org/10.1245/s10434-009-0670-7
  3. Castellanos JA, Merchant NB (2014). Intensity of follow-up after pancreatic cancer resection. Ann Surg Oncol, 21, 747-51. https://doi.org/10.1245/s10434-013-3289-7
  4. Chen SH, Dallas MR, Balzer EM, et al (2012). Mucin 16 is a functional selectin ligand on pancreatic cancer cells. FASEB J, 26, 1349-59. https://doi.org/10.1096/fj.11-195669
  5. Cwik G, Wallner G, Skoczylas T, et al (2006). Cancer antigens 19-9 and 125 in the differential diagnosis of pancreatic mass lesions. Arch Surg, 141, 968-73. https://doi.org/10.1001/archsurg.141.10.968
  6. Emoto S, Ishigami H, Yamashita H, et al (2012). Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination. Gastric Cancer, 15, 154-61. https://doi.org/10.1007/s10120-011-0091-8
  7. Ferrone CR, Finkelstein DM, Thayer SP, et al (2006). Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol, 24, 2897-902. https://doi.org/10.1200/JCO.2005.05.3934
  8. Haglund C (1986). Tumour marker antigen CA125 in pancreatic cancer: a comparison with CA19-9 and CEA. J Clin Oncol, 54, 897-901.
  9. Haridas D, Chakraborty S, Ponnusamy MP, et al (2011). Pathobiological implications of MUC16 expression in pancreatic cancer. PloS one, 6, 26839. https://doi.org/10.1371/journal.pone.0026839
  10. Hartwig W, Strobel O, Hinz U, et al (2013). CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. Ann Surg Oncol, 20, 2188-96. https://doi.org/10.1245/s10434-012-2809-1
  11. Hata S, Sakamoto Y, Yamamoto Y, et al (2012). Prognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancer. Ann Surg Oncol, 19, 636-41. https://doi.org/10.1245/s10434-011-2020-9
  12. Humphris JL, Chang DK, Johns AL, et al (2012). The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol, 23, 1713-22. https://doi.org/10.1093/annonc/mdr561
  13. Katz MH, Varadhachary GR, Fleming JB, et al (2010). Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol, 17, 1794-801. https://doi.org/10.1245/s10434-010-0943-1
  14. Kondo N, Murakami Y, Uemura K, et al (2010). Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer. Ann Surg Oncol, 17, 2321-9. https://doi.org/10.1245/s10434-010-1033-0
  15. Kouris NT, Zacharos ID, Kontogianni DD, et al (2005). The significance of CA125 levels in patients with chronic congestive heart failure. Correlation with clinical and echocardiographic parameters. Eur J Heart Fail, 7, 199-203. https://doi.org/10.1016/j.ejheart.2004.07.015
  16. Lim JE, Chien MW, Earle CC (2003). Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg, 237, 74-85. https://doi.org/10.1097/00000658-200301000-00011
  17. Liu L, Xu H, Wang W, Wu C, et al (2014). A preoperative serum signature of CEA /CA125 /CA19-9 >/= 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer. Int J Cancer. [Epub ahead of print]
  18. Longuespee R, Boyon C, Desmons A, et al (2012). Ovarian cancer molecular pathology. Cancer Metastasis Rev, 31, 713-32. https://doi.org/10.1007/s10555-012-9383-7
  19. Miralles C, Orea M, Espana P, et al (2003). Cancer antigen 125 associated with multiple benign and malignant pathologies. Ann Surg Oncol, 10, 150-4. https://doi.org/10.1245/ASO.2003.05.015
  20. Motoi F, Rikiyama T, Katayose Y, et al (2011). Retrospective evaluation of the influence of postoperative tumor marker status on survival and patterns of recurrence after surgery for pancreatic cancer based on RECIST guidelines. Ann Surg Oncol, 18, 371-9. https://doi.org/10.1245/s10434-010-1311-x
  21. Rapellino M, Piantino P, Pecchio F, et al (1994). Disappearance curves of tumor markers after radical surgery. Int J Biol Markers, 9, 33-7.
  22. Schlieman MG, Ho HS, Bold RJ (2003). Utility of tumor markers in determining resectability of pancreatic cancer. Arch Surg, 138, 951-5 https://doi.org/10.1001/archsurg.138.9.951
  23. Schmidt C (2011). CA-125: a biomarker put to the test. J Natl Cancer Inst, 103, 1290-1. https://doi.org/10.1093/jnci/djr344
  24. Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30. https://doi.org/10.3322/caac.21166
  25. Tempero MA, Arnoletti JP, Behrman S, et al (2010). Pancreatic adenocarcinoma. J Natl Compr Canc Netw, 8, 972-1017.
  26. Tse BW, Collins A, Oehler MK, et al (2014). Antibody-based immunotherapy for ovarian cancer: where are we at? Ann Oncol, 25, 322-31. https://doi.org/10.1093/annonc/mdt405
  27. Tzeng CW, Abbott DE, Cantor SB, et al (2013). Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis. Ann Surg Oncol, 20, 2197-203. https://doi.org/10.1245/s10434-013-2889-6
  28. Wagner PL, Austin F, Sathaiah M, et al (2013). Significance of serum tumor marker levels in peritoneal carcinomatosis of appendiceal origin. Ann Surg Oncol, 20, 506-14. https://doi.org/10.1245/s10434-012-2627-5
  29. Xu HX, Chen T, Wang WQ, et al (2014). Metabolic tumour burden assessed by (1)(8)F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection. Eur J Nucl Med Mol Imaging, 41, 1093-102. https://doi.org/10.1007/s00259-014-2688-8
  30. Zhang P, Zou M, Wen X, et al (2014). Development of serum parameters panels for the early detection of pancreatic cancer. Int J Cancer, 134, 2646-55. https://doi.org/10.1002/ijc.28584